miR-718 is involved in malignancy of papillary thyroid cancer through repression of PDPK1
Section snippets
Background
Papillary thyroid cancer(PTC) accounts for around 85% of thyroid cancers and is largely well-differentiated with a good prognosis [1]. However, its incidence has risen dramatically in the past few decades, faster than any other malignancy for all ethnic backgrounds and both sexes over the same period [2]. Mortality rates have also increased for patients diagnosed with advanced-stage PTC [3]. This concerning rise in mortality is due in large part to the challenges of effectively treating
Clinical sample
15 Pairs of PTC and adjacent normal tissues were obtained from patients who underwent surgery at the First Hospital of Harbin from 2015 to 2017. The fresh tissue samples were freshly frozen and stored at −80 °C for further analysis. No chemotherapy or radiotherapy was administered to any PTC patients prior to surgeries. Disease histopathology was reviewed by two pathologists according to World Health Organization criteria. Written informed consent was obtained from all patients. The study was
miR-718 is downregulated in PTC samples
Based on GSE73182 dataset including 19 PTC samples, miR-718 expression was significantly downregulated (P < 0.05) in cancer tissues as compared to normal papillary thyroid tissues (Fig. 1A). To further confirm miR-718 expression levels in PTC, we analyzed mRNA levels of miR-718 in 15 PTC patients samples as compared to 15 matched noncancerous tissues by RT-PCR. Expression of miR-718 was significantly decreased in human PTC samples (Fig. 1B, P < 0.001). In addition, we analyzed miR-718
Discussion
In the present study, we have identified miR-718 as a crucial negative regulator of PTC cell proliferation, growth, metastatic ability, and glucose metabolism. We began this study with the hypothesis that miR-718, which has been shown to act as a tumor suppressor in a variety of cancers [[12], [13], [14]], would play a similar anti-oncogenic role in PTC. By evaluating the expression levels of miR-718 in resected human PTC tissues and cell lines, we substantiated this hypothesis, finding that
Conflict of interest
The authors declare that they have no conflict of interests.
Acknowledgement
None.
References (36)
- et al.
Refining the eighth edition AJCC TNM classification and prognostic groups for papillary thyroid cancer with lateral nodal metastasis
Oral. Oncol.
(2018) MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing
Cell
(2003)- et al.
MicroRNA and cancer
Mol. Oncol.
(2012) - et al.
MicroRNA functions in stress responses
Mol. Cell
(2010) - et al.
MiR-718 represses VEGF and inhibits ovarian cancer cell progression
FEBS Lett.
(2014) - et al.
PDK1, the master regulator of AGC kinase signal transduction
Semin. Cell Dev. Biol.
(2004) - et al.
Role of Akt/protein kinase B in metabolism
Trends Endocrinol. Metab.
(2002) - et al.
Long non-coding RNA PVT1 promotes glycolysis and tumor progression by regulating miR-497/HK2 axis in osteosarcoma
Biochem. Biophys. Res. Commun.
(2017) - et al.
MicroRNAs–targeting and target prediction
New Biotechnol.
(2010) - et al.
Thyroid cancer epidemiology and prognostic variables
Clin. Oncol. R. Coll. Radiol. (R. Coll. Radiol.)
(2010)
The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors
Mol. Cell. Endocrinol.
Increasing incidence of thyroid cancer in the United States, 1973-2002
JAMA
Current advances in thyroid Cancer management. Are we ready for the epidemic rise of diagnoses?
Int. J. Mol. Sci.
Projecting survival in papillary thyroid cancer: a comparison of the seventh and eighth editions of the American Joint Commission on Cancer/Union for International Cancer control staging systems in two contemporary national patient cohorts
Thyroid
MicroRNA expression profiles classify human cancers
Nature
miRNA dysregulation and the risk of metastasis and invasion in papillary thyroid cancer: a systematic review and meta-analysis
Oncotarget
Potential of liquid biopsy in Papillary Thyroid Carcinoma in context of miRNA, BRAF and p53 mutation
Curr. Drug Targets
miRBase: microRNA sequences, targets and gene nomenclature
Nucleic Acids Res.
Cited by (17)
MiR-451a promotes cell growth, migration and EMT in osteosarcoma by regulating YTHDC1-mediated m6A methylation to activate the AKT/mTOR signaling pathway
2022, Journal of Bone OncologyCitation Excerpt :Moreover, we probed into the regulatory mechanism of miR-451a on PDPK1 in osteosarcoma. PDPK1 has been reported to be implicated in malignancy of cervical cancer [31], papillary thyroid cancer [32], prostate cancer [33], hepatocellular carcinoma [34]. Herein, bioinformatics prediction showed that miR-451a could bind to PDPK1, but with low predicted interactions.
Circular RNA hsa_circ_0004015 regulates the proliferation, invasion, and TKI drug resistance of non-small cell lung cancer by miR-1183/PDPK1 signaling pathway
2019, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Accumulating evidences have suggested that PDPK1 may involve in the pathogenesis of multiple human tumors by interacting with miRNAs. For instance, PDPK1 was reported to be inhibited by miR-718 and then affected the progression of papillary thyroid cancer [26]. In the present study, we demonstrated PDPK1 was negatively regulated by miR-1183.
MiR-125a-5p suppresses bladder cancer progression through targeting FUT4
2018, Biomedicine and PharmacotherapyCitation Excerpt :Through comparing, we identified that miR-125a-5p was expressed lower in BCa cells. Considering the regulatory effect of miRNAs on the biological function of cancer cells [39–42], we performed gain-of-function experiments in two BCa cell lines (J82 and T24). According to the experimental results of MTT and colony formation, proliferation ability of BCa cells was efficiently suppressed by overexpressing miR-125a-5p.
MicroRNAs as the critical regulators of cell migration and invasion in thyroid cancer
2022, Biomarker Research